- Shares of nano cap Aastrom Biosciences (ASTM +25.4%) roar ahead on a 12x surge in volume. Today's bullish action follows yesterday's 24% up move.
- Market chatter says that the firm will report good news from its phase 2 clinical trial of ixmyelocel-T at the upcoming Regen Med Investor Day on March 26 in Ann Arbor, MI.
- The company's market cap is only $25M. Average daily turnover is a modest 200K shares. Investors should be cautious here.
at MarketWatch.com (Jan 2, 2013)